ATE314076T1 - Fosinopril-formulierung - Google Patents

Fosinopril-formulierung

Info

Publication number
ATE314076T1
ATE314076T1 AT03706893T AT03706893T ATE314076T1 AT E314076 T1 ATE314076 T1 AT E314076T1 AT 03706893 T AT03706893 T AT 03706893T AT 03706893 T AT03706893 T AT 03706893T AT E314076 T1 ATE314076 T1 AT E314076T1
Authority
AT
Austria
Prior art keywords
fosinopril
formulation
fosinoprilat
ace
prodrug
Prior art date
Application number
AT03706893T
Other languages
English (en)
Inventor
Reynir Eyjolfsson
Original Assignee
Actavis Group Hf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36715398&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE314076(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Actavis Group Hf filed Critical Actavis Group Hf
Application granted granted Critical
Publication of ATE314076T1 publication Critical patent/ATE314076T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT03706893T 2002-03-19 2003-03-19 Fosinopril-formulierung ATE314076T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IS6315A IS1935B (is) 2002-03-19 2002-03-19 Fósínópríl lyfjasamsetning
PCT/IS2003/000013 WO2003077929A1 (en) 2002-03-19 2003-03-19 Fosinopril formulation

Publications (1)

Publication Number Publication Date
ATE314076T1 true ATE314076T1 (de) 2006-01-15

Family

ID=36715398

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03706893T ATE314076T1 (de) 2002-03-19 2003-03-19 Fosinopril-formulierung

Country Status (13)

Country Link
US (1) US7045511B2 (de)
EP (1) EP1531831B1 (de)
AT (1) ATE314076T1 (de)
AU (1) AU2003208599A1 (de)
DE (1) DE60303041T2 (de)
DK (1) DK1531831T3 (de)
EA (1) EA008171B1 (de)
ES (1) ES2256721T3 (de)
IS (1) IS1935B (de)
NO (1) NO20044390L (de)
PT (1) PT1531831E (de)
UA (1) UA78988C2 (de)
WO (1) WO2003077929A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2322854T3 (es) * 2003-06-26 2009-06-30 Teva Pharmaceutical Industries Limited Composiciones farmaceuticas estables de derivados del acido 2-aza-biciclo(3.3.0)-octano-3-carboxilico.
US20050095287A1 (en) * 2003-10-29 2005-05-05 Matharu Amol S. Fosinopril composition
GB2411355B (en) * 2004-02-27 2006-02-22 Niche Generics Ltd Pharmaceutical composition
MX2007008392A (es) * 2005-02-11 2007-09-06 Aventis Pharma Inc Esteres de acido propano-fosfinico sustituido.
WO2006100602A2 (en) * 2005-03-22 2006-09-28 Aurobindo Pharma Ltd Immediate release stable solid oral dosage forms op fosinopril
KR20080112387A (ko) * 2006-04-19 2008-12-24 테바 파마슈티컬 인더스트리즈 리미티드 2-아자-비사이클로[3.3.0]-옥탄-3-카르복실산 유도체의 안정한 약학 조성물
GB0612540D0 (en) * 2006-06-23 2006-08-02 Novartis Ag Galenical formulations of organic compounds
ATE406173T1 (de) * 2006-07-10 2008-09-15 Teva Pharma Stabile zubereitung enthaltend eine kombination aus einer feuchtigkeitsempfindlichen aktiven substanz und einer zweiten aktiven substanz und verfahren zur herstellung der zubereitung.
US20140179712A1 (en) 2012-12-21 2014-06-26 Astrazeneca Ab Pharmaceutical formulation of n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl]benzamide

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4337201A (en) * 1980-12-04 1982-06-29 E. R. Squibb & Sons, Inc. Phosphinylalkanoyl substituted prolines
US5006344A (en) 1989-07-10 1991-04-09 E. R. Squibb & Sons, Inc. Fosinopril tablet formulations
US6521647B2 (en) * 2000-04-04 2003-02-18 Pfizer Inc. Treatment of renal disorders
CA2330904C (en) * 2001-01-11 2006-10-24 Bernard Charles Sherman Fosinopril sodium tablet formulation
JP2005508978A (ja) * 2001-11-02 2005-04-07 ファイザー・プロダクツ・インク Pde9阻害薬によるインスリン抵抗性症候群及び2型糖尿病の治療
ITMI20012366A1 (it) * 2001-11-09 2003-05-09 Farmatron Ltd Sistemi terapeutici stabilizzati a rilascio immediato e/o modificato per la somministrazione orale di principi attivi e/o eccipienti e/o ali

Also Published As

Publication number Publication date
ES2256721T3 (es) 2006-07-16
US7045511B2 (en) 2006-05-16
EP1531831A1 (de) 2005-05-25
DK1531831T3 (da) 2006-05-15
US20050256086A1 (en) 2005-11-17
IS6315A (is) 2003-09-20
UA78988C2 (en) 2007-05-10
WO2003077929A1 (en) 2003-09-25
NO20044390L (no) 2004-12-15
PT1531831E (pt) 2006-05-31
EA200401218A1 (ru) 2005-12-29
DE60303041T2 (de) 2006-08-24
DE60303041D1 (de) 2006-02-02
IS1935B (is) 2004-06-16
AU2003208599A1 (en) 2003-09-29
EA008171B1 (ru) 2007-04-27
EP1531831B1 (de) 2005-12-28

Similar Documents

Publication Publication Date Title
CO5590918A2 (es) Formulaciones
CY1109457T1 (el) Παραγωγο aminoαλκοολης ή παραγωγο φωσφονικου οξεος και φαρμακευτικη συνθεση που τα περιεχει
MA29854B1 (fr) Nouvelle formulation
MXPA04004464A (es) Compuestos de heteroarilo sustituido con azabiciclo para el tratamiento de enfermedades.
MA29857B1 (fr) Derives de triazolopyridine en tant qu'inhibiteurs de lipases et phospholipases
MY138252A (en) Azabicyclic-substitud fused-heteroaryl compounds for the treatment of disease
NO20081050L (no) Kaspaseinhibitor-prodroger
SG10201809390QA (en) Modulators of indoleamine 2,3-dioxygenase and methods of using the same
NO20060847L (no) Substituert 2-aminotetralin til behandling av depresjon
ATE554084T1 (de) N-hydroxyacrylamidverbindungen
MX2009003926A (es) Composiciones de fenilalquilamino-carbamato.
NO20074544L (no) Inhibering av HER2-losriving med matriksmetalloproteaseantagonister
MX2009003929A (es) Composiciones de fenilalquil carbamato.
MA29278B1 (fr) Composition pharmaceutique comprenant un derive de l'indolylmaleimide
MXPA04006266A (es) Pirimidotriazinas como inhibidores de fosfatasa.
ATE314076T1 (de) Fosinopril-formulierung
BR0112245B1 (pt) Éster de ácido 4-alcóxi-ciclohexano-1-amino-carboxílico
EA200601608A1 (ru) Способ производства твёрдой фармацевтической композиции
WO2008036316A3 (en) Piperidine and pyrrolidine beta-secretase inhibitors for the treatment of alzheimer's disease
ATE464043T1 (de) Pharmazeutische zusammensetzung enthaltend l- arginin
BRPI0411218A (pt) formulações alvejantes fluorescentes estáveis em estocagem
TNSN06012A1 (en) Emulsifying systems containing azetidine derivatives
WO2006031929A3 (en) Thiazolopyridine kinase inhibitors
EA200801634A1 (ru) Твердая фармацевтическая композиция, содержащая ирбесартан
TW200640860A (en) Lercanidipine free base

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1531831

Country of ref document: EP